Read by QxMD icon Read

Journal of Drug Targeting

Chia-Wei Lin, Ming-Shiou Jan, Jung-Hua Steven Kuo
Intercellular communication is known to be involved in various stages of tumor development and metastasis through the secretion of extracellular vesicles (EVs) containing messengers such as microRNAs (miRNAs). Therefore, this study explored miRNA profiles in cancer cell-derived EVs after non-viral gene delivery in order to better understand the molecular information of intercellular communication in cancer cells after gene delivery. Two commonly used non-viral vectors (Lipofectamine 2000 and jet polyethylenimine) were used for the delivery of gene fluorescent protein plasmid in HeLa cancer cells...
June 22, 2018: Journal of Drug Targeting
Jing-Jing Chen, Yu-Hang Gong, Ling He
G-protein coupled receptor 40 (GPR40) is also known as free fatty acid receptor 1. It is a typical 7 transmembrane receptor and currently the natural receptor of the saturated or unsaturated long-chain fatty acids. It could trigger the intracellular signaling pathway when combined with the free long-chain fatty acids, thereby controlling cells physiological function. In this review, we summarized the relationships and the potential mechanisms between the promising target GPR40, and pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia...
June 22, 2018: Journal of Drug Targeting
Sepideh Zununi Vahed, Nazanin Fathi, Mohammad Samiei, Solmaz Maleki Dizaj, Simin Sharifi
Based on exceptional advantages of aptamers, increasing attention has been presented in the utilize of them as targeted ligands for cancer drug delivery. Recently, the progress of aptamer- targeted nanoparticles has presented new therapeutic systems for several types of cancer with decreased toxicity and improved efficacy. We highlight some of the promising formulations of aptamer-conjugated polymeric nanoparticles for specific targeted drug delivery to cancer cells. This review paper focuses on the current progresses in the use of the novel strategies to aptamer-targeted drug delivery for chemotherapy...
June 21, 2018: Journal of Drug Targeting
Amir Barzegar Behrooz, Amir Syahir, Syahida Ahmad
CD133 (prominin-1), a pentaspan membrane glycoprotein, is one of the most well-characterized biomarkers used for the isolation of cancer stem cells (CSCs). The presence of CSCs is one of the main causes of tumor reversal and resilience. Accumulating evidence has shown that CD133 might be responsible for CSCs tumorigenesis, metastasis, and chemoresistance. It is now understood that CD133 interacts with the Wnt/β-catenin and PI3K-Akt signaling pathways. Moreover, CD133 can upregulate the expression of FLICE-like inhibitory protein (FLIP) in CD133-positive cells, inhibiting apoptosis...
June 18, 2018: Journal of Drug Targeting
Zhijie Wang, Wenqi Yuan, Bo Li, Xueming Chen, Yanjun Zhang, Chuanjie Chen, Mei Yu, Yucai Xiu, Wenhua Li, Jiangang Cao, Xin Wang, Wen Tao, Xiaoling Guo, Shiqing Feng, Tianyi Wang
The present study explored a key miRNA that plays a vital role in sciatic nerve conditioning injury promoting repair of injured dorsal column, and validated its function. Microarray analysis revealed miR-17-5p expression decreased sharply at 3, 7 and 14 days in the sciatic nerve conditioning injury group compared with the simple dorsal column lesion group. After miR-17-5p inhibition in DRG neurons, GAP-43 expression was upregulated and neurite growth was increased. STAT3 together with p-STAT3 showed opposite trends with miR-17-5p...
June 7, 2018: Journal of Drug Targeting
Y Han, X Li, C Ma, X Ji, T Li, X Zheng, J Zhang, J Yan, D Zhang, J Bai
MicroRNAs (miRNAs) are small, noncoding RNAs that have tissue- and cell-specific expression. They have the ability to regulate the malignant proliferation and transformation of tumor cells. The research focused on the expression and role of miR-1297 in melanoma. We firstly found that miR-1297 is up-regulated in melanoma tissues and cell lines. Functionally, phosphatase and tension homology deleted on chromsome ten gene (PTEN) was used as a potential target for miR-1297 and detected using Western blotting and immunohistochemistry (IHC)...
June 6, 2018: Journal of Drug Targeting
Gaorui Cai, Wei Liu, Yong He, Jianghong Huang, Li Duan, Jianyi Xiong, Lijun Liu, Daping Wang
Either osteoarthritis or sports-related injuries can lead to cartilage defects, whereas both chondrocyte self-renewal and conventional treatments face limitations. In cartilage regenerative medicine, growth factors are commonly used to induce chondrogenic differentiation of stem cells. However, application of growth factors is confined by some drawbacks. Emerging small molecules are regarded as an alternative for cartilage regeneration. A recently discovered small-molecule compound, kartogenin (KGN), has been proven to be a chondrogenic and chondroprotective agent and is more effective in inducing cartilage regeneration when compared with growth factors...
May 30, 2018: Journal of Drug Targeting
Mengyao Liu, Yanan Zhang, Siyu Sun, Abdur Rauf Khan, Jianbo Ji, Mingshi Yang, Guangxi Zhai
Electrospun, an advanced technology, has been successfully employed for fibers production and offers many merits in novel drug delivery systems (DDSs). In recent years, electrospun has gained significant attention and attraction of the scientists in soaring numbers. This technology is superior to other technologies in fabricating the fibers ranging from micrometers to manometers scale. The selection of appropriate polymers, electrospun processes and electrospun parameters play important roles in controlling the drug release while, treating serious illness...
May 25, 2018: Journal of Drug Targeting
Yong Guan, Yajie He, Shaoping Lv, Xiaoqun Hou, Luo Li, Jianjun Song
OBJECTIVE: The HOX gene is expressed in neoplasias occurred in multiple tissues, such as the colon, lung, and breast. However, the effects of the HOX gene on glioblastoma (GBM) remain poorly understood. We examined HOXC10 expression in GBM tissues and cells, analyzed its effect on GBM prognosis, and finally assessed its possible underlying mechanisms in this study. METHODS: HOXC10 expression levels and its prognostic effects on GBM tissues were analyzed based on The Cancer Genome Atlas (TCGA) and ONCOMINE database...
May 16, 2018: Journal of Drug Targeting
Pravin Shende, Chirag Patel
Diabetes is a condition that is not completely treatable but life of a diabetic patient can be smoothed by preventing or delaying the associate conditions like diabetic retinopathy, nephropathy, impaired wound healing process etc. Apart from conventional methods to regulate diabetic condition, new techniques using siRNA have been emerged to prevent the associated conditions. This paper focuses on how siRNA used as a tool to silence the expression of genes which plays critical role in pathogenesis of these conditions...
May 14, 2018: Journal of Drug Targeting
Duy Hieu Truong, Thi Thu Phuong Tran, Hanh Thuy Nguyen, Cao Dai Phung, Thanh Tung Pham, Chul Soon Yong, Jong Oh Kim, Tuan Hiep Tran
Immunotherapy holds tremendous promise for improving cancer treatment in which an appropriate stimulator may naturally trigger the immune system to control cancer. Up-to-date, adoptive T-cell therapy has received two new FDA approvals that provide great hope for some cancer patient groups. Nevertheless, expense and safety-related issues require further study to obtain insight into targets for efficient immunotherapy. The development of material science was largely responsible for providing a promising horizon to strengthen immunoengineering...
May 9, 2018: Journal of Drug Targeting
K R Gajbhiye, V Gajbhiye, Imtiaz A Siddiqui, J M Gajbhiye
The integrins αv β3 play a very imperative role in angiogenesis and are overexpressed in endothelial cells of the tumor. Recent years have witnessed huge exploration in the field of αv β3 integrin-mediated bioactive targeting for treatment of cancer. In these studies, the cRGD peptide has been employed extensively owing to their binding capacity to the αv β3 integrin. Principally, RGD-based approaches comprise of antagonist molecules of the RGD sequence, drug-RGD conjugates, and most importantly tethering of the nanocarrier surface with the RGD peptide as targeting ligand...
May 8, 2018: Journal of Drug Targeting
Kejing Lao, Naichun Ji, Xiaohua Zhang, Wenwei Qiao, Zhishu Tang, Xingchun Gou
Alzheimer's disease (AD) is a chronic neurodegenerative disease, which is considered one of the most intractable medical problems with heavy social and economic costs. The current drugs for AD, including acetylcholinesterase inhibitors (AChEIs) and memantine, a NMDA receptor antagonist, only temporarily ameliorate cognitive decline, but are unable to stop or reverse the progression of dementia. This paper reviewed the recent advance in AD drug development. The drug discovery programs under clinical trials targeting cholinergic system, α7 nicotinic acetylcholine receptors (nAChRs), N-methyl-D-aspartate receptor (NMDAR), β-secretase, γ-secretase modulators, tau, inflammatory mediators and glucagon-like peptide-1 (GLP-1) were discussed...
May 7, 2018: Journal of Drug Targeting
Lingyun Yi, Yanan Zhang, Xiaoqun Shi, Xiyou Du, Xinyi Wang, Aihua Yu, Guangxi Zhai
In recent years, graphene oxide (GO) nanomaterials have attracted wide attention due to their large surface area, strong light sensitivity and good biocompatibility in cancer treatment. The rich oxygen-containing functional groups on the surface provide it with the opportunity to be modified by many functional molecules to expand biological applications and reduce toxicity. In this review, the properties of GO and the methods of surface modification are presented, and the toxicity of GO is analyzed. In addition, the current applications of GO in cancer diagnoses and treatments including biological imaging, drug and gene delivery, phototherapy, and imaging-mediated combination therapy are summarized...
May 7, 2018: Journal of Drug Targeting
Swati Jaiswal, Aditi Chatterjee, Sapna Pandey, Kiran Lata, Ranjith Kumar Gadi, Rajesh Manda, Sanjay Kumar, Maddi Sridhar Reddy, Ravishankar Ramachandran, Kishore K Srivastava
Phosphorylation and dephosphorylation are the key mechanisms for mycobacterial physiology and play critical roles in mycobacterial survival and in its pathogenesis. Mycobacteria evade host immune mechanism by inhibiting phagosome - lysosome fusion in which mycobacterial protein tyrosine phosphatase A (TP) plays an indispensable role. Tyrosine kinase (TK) activated by autophosphorylation; phosphorylates TP, which subsequently leads to increase in its phosphatase activity. The activated TP after getting phosphorylated is secreted in phagosome of macrophage...
May 3, 2018: Journal of Drug Targeting
Chaopin Yang, Yue Li, Meng Du, Zhiyi Chen
As a non-invasive and real-time diagnostic technique, ultrasound has provided a novel strategy for targeted treatment. With the rapid development of ultrasonic technique and ultrasound contrast agents (UCAs), spatiotemporally controllable application of ultrasound with or without UCAs makes it possible for site-specific delivery of therapeutic agents and targeted modulation with minimal side effects, which indicated a promising therapy in clinical use. This review will describe the main mechanism of targeted therapy induced by ultrasound briefly, then focus on the current application of ultrasound mediated targeted therapy in various fields including tumour, cardiovascular disease, central nervous system, skeletal muscle system diseases and stem cells therapy...
April 27, 2018: Journal of Drug Targeting
Liping Zhang, Yanan Shi, Yina Song, Dongyu Duan, Xuemei Zhang, Kaoxiang Sun, Youxin Li
Safe and effective oral delivery of peptide is a challenge. Here, we used exenatide and zinc ions (Zn2+ ) to form a complex to explore a meaningful oral-targeted drug-delivery system. Polyethylene glycol-poly(lactic acid-co-glycolic acid) (PEG-PLGA) was used to prepare nanoparticles (NPs) to escape the degradation caused by gastrointestinal enzymes. Transferrin (Tf) was used as a targeting group. PEG-PLGA-NPs and Tf-modified exenatide-Zn2+ -loaded NPs (Tf-PEG-PLGA-NPs) were uniformly sized spheres according to transmission electron microscopy...
April 16, 2018: Journal of Drug Targeting
Lin Yu, Yuqin Yao, Yuxi Wang, Shijie Zhou, Qinhuai Lai, Ying Lu, Yu Liu, Ruirui Zhang, Ruixue Wang, Chuang Liu, Lantu Gou, Xiaoxin Chen, Yamei Yu, Qiang Chen, Jinliang Yang
Antibody-drug conjugates (ADCs) have been successfully applied clinically as target drugs for cancer. In this study, anti-neural cell adhesion molecule also called CD56 antibody-monomethyl auristatin E (MMAE) conjugate named Promiximab-MMAE was prepared by conjugation of microtubule inhibitor MMAE with Promiximab. The average drug-to-antibody ratio (DAR) of Promiximab-MMAE was 3.13 as analysed by liquid chromatography-mass spectrometry/ mass spectrometry (LC-MS/MS). The targeting capacity and affinity kinetics of Promiximab-MMAE were similar to that of Promiximab after being conjugated with MMAE as tested by flow cytometry and biolayer interferometry analysis...
April 13, 2018: Journal of Drug Targeting
Yue Chen, Ming Ji, Shen Zhang, Nina Xue, Heng Xu, Songwen Lin, Xiaoguang Chen
Inhibition of the signal transducer and activator of transcription 3 (STAT3) signalling pathway has been considered as a novel therapeutic strategy to treat human cancers with constitutively active STAT3. In this study, we screened 1563 compounds and identified Bt354 as a new small-molecule inhibitor of the STAT3 signalling pathway. The effect of Bt354 on STAT3 activity was initially screened and Bt354 significantly inhibited STAT3 activity in a dual luciferase assay. Bt354 inhibited the proliferation of cancer cells in a dose- and time-dependent manner...
April 6, 2018: Journal of Drug Targeting
Shuang Fu, Xiaodong Xu, Yu Ma, Shubiao Zhang, Shufen Zhang
Integrin αv β3 is restrictedly expressed on angiogenic blood vessels and tumour cells. It plays a key role in angiogenesis for tumour growth and metastasis. RGD peptide can specifically recognise the integrin αv β3 , which serves as targeted molecular for anti-angiogenesis strategies. Therefore, the targeted delivery of therapeutics by RGD peptide-based non-viral vectors to tumour vasculature and tumour cells is recognised as a promising approach for treating cancer. In this review, we illustrate the interaction between RGD peptide and integrin αv β3 from different perspectives...
April 6, 2018: Journal of Drug Targeting
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"